An interventional study of eShunt® Implant in Hydrocephalus and Hydrocephalus, Communicating, sponsored by CereVasc Inc. Terminated at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-11-22.
Sponsored by CereVasc Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Hydrocephalus with a site in United States — 22 open to participants now, 26 under way, none of them phase 3. Hydrocephalus · United States.
Among the 77 studies in Hydrocephalus with a site in United States, this one is the 38th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2022, is one of 31 with no phase, and was the 56th registered.
190 studies on the registry are indexed under Hydrocephalus; 52 are open to participants now.
Browse Hydrocephalus studies →22 of the 77 studies in Hydrocephalus with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital of Philadelphia · Sites in United States
Ages 1 min–18 mo
Rhaeos, Inc. · Sites in United States
Milton S. Hershey Medical Center · Sites in United States
Ages 18+
Rhaeos, Inc. · Sites in United States
Rhaeos, Inc. · Sites in United States
Ages 2+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Hydrocephalus studies recruiting now, 18 (58%) set no upper age limit and 6 (19%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 3 · Phase 4 3
First in 1985; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 41 across 97 interventional studies indexed under Hydrocephalus.
Median enrollment 33 across the 42 interventional studies, 66 across the 34 observational. Of the 41 that completed or were terminated, 8 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 77 have an industry lead sponsor. The 10 most frequent:
CereVasc Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.
CereVasc Inc has 4 studies filed under Hydrocephalus — fewer than ten, so there is no comparison to draw.
11 of the studies in Hydrocephalus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06368648CoMind Technologies LimitedCoMind Early Feasibility Study | 2026-11 |
| NCT07679035Rhaeos, Inc.Study of Shunt Flow Under Different Valve Settings Using a Wireless Sensor | 2026-11-30 |
| NCT02601339Boston Children's HospitalNIRS Monitoring in Premature Infants | 2026-12 |
| NCT06253858Milton S. Hershey Medical CenterUltrasound (US) Guided External Ventricular Catheter Placement | 2026-12-01 |
| NCT07478926Rhaeos, Inc.Flow Detection in Open and Closed Shunt Valve Periods | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 77 studies in Hydrocephalus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. The eShunt® Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.
This is a prospective, multi-center, open label, pilot study of the eShunt® System. The study population consists of patients with post-aneurysmal subarachnoid hemorrhage (SAH) treated for increased intracranial pressure (ICP) resulting in symptomatic hydrocephalus using an external ventricular drain (EVD) to facilitate CSF drainage and who cannot be "weaned" from the EVD after the hemorrhagic event.
After completion of the procedure to place the eShunt® device, the ICP will be monitored and recorded for up to 48 hours. Subjects will then return for follow-up visits that include standard neurological evaluations at 30, 60, 90, 180, and 365 days postimplantation; imaging will also be acquired at 30, 90 and 365 days after implant. Subjects will continue to attend follow-up visits every 180 days thereafter until the study is closed or up to 5 years post-implantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Post-aneurysmal SAH with Hunt and Hess Grades I-IV with EVD in place for at least 7 days with the need for a permanent CSF shunt determined through a failed EVD clamping trial defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Device Arm receives the eShunt® Implant
Device: eShunt® Implant
The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
Also known as: eShunt®, eShunt® system
Reduction in ICP
At 24 to 48 hours after eShunt Implant deployment (with EVD remaining clamped) an ICP measurement that indicates: * ICP below 20 cmH2O with no periods longer than 15 minutes above 20 cmH2O * No episodes of ICP above 25 cmH2O with associated symptoms
Time frame: 24-48 hours after eShunt Implant placement
Occurrence of Serious Adverse Events
The number of device and/or procedure-related serious adverse events (SAEs) after the implant procedure will be calculated.
Time frame: 90 days post procedure
Incidence of clinically significant changes in Computed Tomography Imaging (CT/CTA) from baseline.
Clinically significant changes from baseline CT images will be summarized
Time frame: 1 year post procedure
Number of participants with clinically significant changes in physical and neurologic examination assessments from baseline
Clinically significant changes from baseline physical examination and neurologic examination assessments will be summarized
Time frame: 1 year post procedure
Summary of Adverse Events
Tabulation of all Adverse Events collected in the study.
Time frame: 90 days post procedure and at study completion
Changes in Modified Rankin Scale Scores
Changes in Modified Rankin Scale scores from baseline will be summarized.
Time frame: 1 year post procedure
Number of subjects requiring conversion to conventional CSF shunt
Evaluate the need for CSF diversion by conventional CSF shunt insertion within 12 months after eShunt Implant deployment
Time frame: 1 year post procedure
Plan to share: No
Ran from Sep 2022 to primary completion in Sep 2023, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CereVasc Inc